At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 35 enrolled
Drug / intervention
Triptorelin (I.N.N.)drug
Likely dose
Triptorelin (I.N.N.) 11.25mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Follow-up of the Phase III, Multicentre, Non Comparative, One Single Group, Open Study to Assess the Long-term Efficacy and Tolerability of Pamoate of Triptorelin 11.25 mg in Children With Precocious Puberty
In Brief
A Phase 3 clinical trial evaluating Triptorelin (I.N.N.) for Precocious Puberty. Completed, enrolled 35 participants across 10 sites.
Detailed Summary
The purpose of the protocol is to assess the efficacy of triptorelin 11.25 mg with respect to the proportion of children who maintain a regression or stabilisation of sexual maturity until the end of the study.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPrecocious Puberty
CountriesFrance
Collaborators--
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartApr 2008
First PostedMay 2009
Primary CompletionApr 2015
Study CompletionJan 2016
TodayJul 2026
First PostedMay 29, 2009
Enrollment StartApr 1, 2008
Primary CompletionApr 1, 2015
Study CompletionJan 1, 2016
TodayJul 2, 2026
Enrollment to primary: 7 yearsPosted 17.1 years ago
Interventions
Triptorelin (I.N.N.)drug
Decapeptyl® SR 11.25mg